Clario – a leading provider of endpoint data solutions to the clinical trial industry – announced they have acquired NeuroRx, a leader in imaging analysis with expertise in multiple sclerosis.
NeuroRx created a reputation for providing clinical trials with a comprehensive suite of imaging-related services, from protocol assistance to data interpretation and reporting. Since 2011, they have supported the approvals of numerous neurological therapies, including 12 FDA-approved multiple-sclerosis drugs.
Along with the NeuroRx acquisition, Clario recently announced a signed definitive agreement to acquire WCG’s eCOA business. And together, the two acquisitions are expected to strengthen Clario’s scientific expertise and service delivery capabilities in the neuroscience therapeutic area.
KEY QUOTES:
“We’re excited to welcome NeuroRx to Clario. This strategic acquisition reinforces our strong leadership in imaging and further expands our capabilities in neuroscience—an area of immense importance in advancing medical innovation. By augmenting our expertise in this critical therapeutic area, we are even better positioned to support our customers in developing life-changing drugs.”
– Clario’s chief executive officer, Chris Fikry, M.D.
“Since 2002, our team at NeuroRx has been dedicated to advancing imaging science to support the development of breakthrough treatments for neurological diseases. With experience in over 300 clinical trials, we have seen firsthand the impact that advanced image analysis can have on drug development. Joining Clario allows us to expand our reach, increase innovation, and broaden our impact on drug development.”
– NeuroRx’s founder and chief executive officer, Douglas Arnold, M.D., who will be joining Clario as Senior Scientific Advisor
“Neuroscience is one of the most challenging frontiers in medicine, and tackling it requires deep expertise and unwavering commitment. With NeuroRx joining our organization, we are gaining a team of scientists and imaging capabilities that have played a pivotal role in advancing multiple sclerosis drug development, as well supported treatments for Huntington’s, Parkinson’s, and Alzheimer’s diseases. I couldn’t be more excited about what that means for Clario, our customers, and their patients.”
– Clario’s executive vice president and general manager of Clario’s Medical Imaging and Specialty Solutions, Joyce Suhy, Ph. D.
